These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 26600225)

  • 21. Prevalence of S282T mutation in different genotypes of hepatitis C virus from DAA-treated naïve Chinese patients who were chronically infected with HCV.
    Qiao B; Tong YQ; Wang M; Gong WJ; Li Y
    Eur Rev Med Pharmacol Sci; 2018 Aug; 22(16):5305-5311. PubMed ID: 30178855
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Are we nearing the end in the fight against hepatitis C?
    Chua JV; Kottilil S
    Expert Rev Gastroenterol Hepatol; 2017 Jun; 11(6):499-500. PubMed ID: 28335650
    [No Abstract]   [Full Text] [Related]  

  • 23. Hepatitis C virus management: potential impact of nanotechnology.
    Elberry MH; Darwish NHE; Mousa SA
    Virol J; 2017 May; 14(1):88. PubMed ID: 28464951
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Addressing the Challenges of Hepatitis C Virus Resistance and Treatment Failure.
    Colpitts CC; Baumert TF
    Viruses; 2016 Aug; 8(8):. PubMed ID: 27537906
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Genotype 1 hepatitis C virus and the pharmacist's role in treatment.
    Sebhatu P; Martin MT
    Am J Health Syst Pharm; 2016 Jun; 73(11):764-74. PubMed ID: 27126832
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A 2015 roadmap for the management of hepatitis C virus infections in Asia.
    Lim SG; Dan YY
    Korean J Intern Med; 2015 Jul; 30(4):423-33. PubMed ID: 26161008
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Real-world treatment for chronic hepatitis C infection in Germany: Analyses from drug prescription data, 2010-2015.
    Zimmermann R; Kollan C; Ingiliz P; Mauss S; Schmidt D; Bremer V
    J Hepatol; 2017 Jul; 67(1):15-22. PubMed ID: 28189752
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Chronic Hepatitis C in Elderly Patients: Current Evidence with Direct-Acting Antivirals.
    Jhaveri MA; Manne V; Kowdley KV
    Drugs Aging; 2018 Feb; 35(2):117-122. PubMed ID: 29417462
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [A new challenge in clinical practice: resistance to directly acting antivirals in hepatitis C treatment].
    Chen ZW; Hu P; Ren H
    Zhonghua Gan Zang Bing Za Zhi; 2016 Mar; 24(3):165-9. PubMed ID: 27095757
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Telemedicine HCV treatment in department of corrections results in high SVR in era of direct-acting antivirals.
    Syed TA; Cherian R; Lewis S; Sterling RK
    J Viral Hepat; 2021 Jan; 28(1):209-212. PubMed ID: 32854135
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hepatitis C: Issues in Children.
    Lee CK; Jonas MM
    Gastroenterol Clin North Am; 2015 Dec; 44(4):901-9. PubMed ID: 26600227
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Towards hepatitis C virus elimination: Egyptian experience, achievements and limitations.
    Omran D; Alboraie M; Zayed RA; Wifi MN; Naguib M; Eltabbakh M; Abdellah M; Sherief AF; Maklad S; Eldemellawy HH; Saad OK; Khamiss DM; El Kassas M
    World J Gastroenterol; 2018 Oct; 24(38):4330-4340. PubMed ID: 30344418
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Vedroprevir in the management of hepatitis C virus infection.
    Abutaleb A; Kottilil S
    Expert Opin Investig Drugs; 2017 Dec; 26(12):1399-1402. PubMed ID: 29053394
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Resistance detection and re-treatment options in hepatitis C virus-related chronic liver diseases after DAA-treatment failure.
    Sagnelli E; Starace M; Minichini C; Pisaturo M; Macera M; Sagnelli C; Coppola N
    Infection; 2018 Dec; 46(6):761-783. PubMed ID: 30084057
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Epidemiology and treatment of hepatitis C genotypes 5 and 6.
    Al Naamani K; Al Sinani S; Deschênes M
    Can J Gastroenterol; 2013 Jan; 27(1):e8-12. PubMed ID: 23378985
    [TBL] [Abstract][Full Text] [Related]  

  • 36. New advances in the molecular biology of hepatitis C virus infection: towards the identification of new treatment targets.
    Ploss A; Dubuisson J
    Gut; 2012 May; 61 Suppl 1():i25-35. PubMed ID: 22504917
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hepatitis C Virus: A European Perspective.
    Dultz G; Zeuzem S
    Gastroenterol Clin North Am; 2015 Dec; 44(4):807-24. PubMed ID: 26600221
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Update on hepatitis C treatment: systematic review of clinical trials.
    Jhaveri M; Procaccini N; Kowdley KV
    Minerva Gastroenterol Dietol; 2017 Mar; 63(1):62-73. PubMed ID: 27768010
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Eliminating hepatitis C within low-income countries - The need to cure genotypes 4, 5, 6.
    Asselah T; Hassanein T; Waked I; Mansouri A; Dusheiko G; Gane E
    J Hepatol; 2018 Apr; 68(4):814-826. PubMed ID: 29229584
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Prevalence of Mixed Hepatitis C Virus Genotype Infection and Its Effect on the Response to Direct-Acting Antivirals Therapy.
    Hayashi K; Tachi K; Shimizu Y; Nagano K; Ishizu Y; Kuzuya T; Honda T; Ishigami M; Hirooka Y; Hattori M; Goto H
    Intervirology; 2019; 62(1):23-29. PubMed ID: 31207601
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.